Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs
Jesús Horacio Lara-Puente, Juan Manuel Carreño, Weina Sun, Alejandro Suárez-Martínez, Luis Ramírez-Martínez, Francisco Quezada-Monroy, Georgina Paz-De la Rosa, Rosalía Vigueras-Moreno, Gagandeep Singh, Oscar Rojas-Martínez, Héctor Elías Chagoya-Cortés, David Sarfati-Mizrahi, Ernesto Soto-Priante, Constantino López-Macı́as, Florian Krammer, Felipa Castro-Peralta, Peter Palese, Adolfo García‐Sastre, Bernardo Lozano-Dubernard
Abstract
Several highly efficacious vaccines for SARS-CoV-2 have been developed and are used in the population. However, the current production capacity cannot meet the global demand. Therefore, additional vaccines-especially ones that can be produced locally and at low cost-are urgently needed. This work describes preclinical testing of a SARS-CoV-2 vaccine candidate which meets these criteria.